Investment Analysts’ Weekly Ratings Changes for Monte Rosa Therapeutics (GLUE)
Several brokerages have updated their recommendations and price targets on shares of Monte Rosa Therapeutics (NASDAQ: GLUE) in the last few weeks: 10/5/2026 – Monte Rosa Therapeutics was given a new $25.00 price target by Raymond James Financial, Inc.. 10/5/2026 – Monte Rosa Therapeutics had its “buy” rating reaffirmed by Benchmark Co.. 10/1/2026 – Monte […]
10 Oct 00:56 · The Markets Daily